Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma

This study identifies nuclear phosphorylated-ERK staining in post-chemotherapy neuroblastoma samples as a potential prognostic marker for poor outcomes. The findings suggest MAPK pathway activation after treatment may indicate resistance and identify candidates for MEK inhibitor therapy.